About AbFero Pharmaceuticals
AbFero Pharmaceuticals is a company based in Boston (United States) founded in 2016 by Raymond J Bergeron. AbFero Pharmaceuticals has raised $1.78 million across 5 funding rounds from investors including Eureka Network and Cure Parkinson's. AbFero Pharmaceuticals offers products and services including SP-420. AbFero Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Boston, United States
- Founders Raymond J Bergeron
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abfero Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.78 M (USD)
in 5 rounds
-
Latest Funding Round
$500 K (USD), Seed
Mar 22, 2021
-
Investors
Eureka Network
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AbFero Pharmaceuticals
AbFero Pharmaceuticals offers a comprehensive portfolio of products and services, including SP-420.
Lead candidate for treating iron overload and related conditions.
Funding Insights of AbFero Pharmaceuticals
AbFero Pharmaceuticals has successfully raised a total of $1.78M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $500 thousand completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AbFero Pharmaceuticals
AbFero Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Eureka Network and Cure Parkinson's.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Business management consulting services are offered to clients.
|
Locked | Locked | Locked |
Investor details for AbFero Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AbFero Pharmaceuticals
Investment portfolio details for AbFero Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AbFero Pharmaceuticals
Detailed financials for AbFero Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abfero Pharmaceuticals Comparisons
Peer comparison for AbFero Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AbFero Pharmaceuticals
AbFero Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of AbFero Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abfero Pharmaceuticals
Complete news archive for AbFero Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AbFero Pharmaceuticals
AbFero Pharmaceuticals was founded in 2016 and raised its 1st funding round 3 years after it was founded.
AbFero Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
AbFero Pharmaceuticals is a funded company, having raised a total of $1.78M across 5 funding rounds to date.
AbFero Pharmaceuticals was founded in 2016 and is based in Boston, United States. Oral iron chelators are developed by the company within the biotechnology sector for addressing iron overload diseases. The lead candidate, SP-420, is designed as an oral treatment for genetic conditions leading to retinal and neurologic disorders, as well as other debilitating effects. Additional solutions are provided for age-related macular degeneration, Parkinsons disease, and traumatic brain injury.
AbFero Pharmaceuticals's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
AbFero Pharmaceuticals offers SP-420.
AbFero Pharmaceuticals has 2 investors. Key investors include Eureka Network, and Cure Parkinson's.